Posted: 14 November 2023 Neuren Pharmaceuticals (ASX: NEU) has been presented with the 2023 Australian Growth Company of the Year Award for Health and Life Sciences. Neuren CEO Jon Pilcher commented: “We were very pleased to be recognized…
Posted: 13 November 2023 Peter Mac scientists have been part of a nationwide push to get an important genetic test for blood cancer funded by Medicare. Approved by the federal government earlier this year and now funded in…
Posted: 13 November 2023 Monash University has been named Australia’s top research institution by The Australian in its annual list of the country’s top researchers and research institutions. Of the 250 fields of academic endeavour identified by The Australian Research Magazine…
Posted: 13 November 2023 Peter Mac will be part of a pioneering initiative driven by Moderna to bring together key Australian medical research institutes to form a mRNA Platform Incubator Network. The mRNA Platform Incubator Network aims to…
Posted: 13 November 2023 Researchers have invented an experimental wearable device that generates power from a user’s bending finger and can create and store memories, in a promising step towards health monitoring and other technologies. The innovation features…
Posted: 13 November 2023 VivaZome Therapeutics Pty Ltd (“VivaZome”) is presenting three posters at the 6th annual meeting of the Australian and New Zealand Society of Extracellular Vesicles (ANZSEV) being held this week in the Barossa Valley, South…
Posted: 9 November 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has successfully completed enrolment in its ATH434-201 Phase 2…
Posted: 6 November 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the open-label safety lead-in of its integrated AIPAC-003 Phase…
Posted: 6 November 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial…
Posted: 6 November 2023 Amplia Therapeutics Limited is pleased to announce the completion of the Phase 1b stage of the ongoing ACCENT clinical trial in first-line patients with advanced pancreatic cancer. A safe and well tolerated dose of…
Posted: 3 November 2023 Optiscan Imaging Limited (ASX: OIL) is pleased to announce a key leadership appointment reflecting the continued commercial expansion of the Company. The Company is delighted to announce the appointment of Brendan Fafiani to the…
Posted: 3 November 2023 Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificial intelligence (AI). Atmo Biosciences is building the…